Company We are GSK As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.
GSK plc (LSE/NYSE: GSK) today announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.
GSK to invest $30 billion in R&D and Manufacturing in the United States ...
Careers We are GSK At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Unfortunately, we cannot provide comprehensive information about our products here, in compliance with regulations. If you are a healthcare professional, you can access more product information on our GSKPro website. In the US, if you are a patient and have questions about our medicines, please contact the GSK Response Center.
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs.
Promising efficacy and safety profile supports start of five pivotal phase III trials in 2026 GSK plc (LSE/NYSE: GSK) today announced positive findings from its global phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen.
Disaster response - Contact our US Response Center online if you need help accessing your GSK medicines during a natural disaster. Patient Assistance Programs - We are committed to helping patients access our medications, and have a long history of providing a range of programs to help them.